Bioprofarma Bagó is proud to present the launch of GOMBRICH® cabazitaxel, for its Oncology Business Unit.

GOMBRICH® cabazitaxel is used for the treatment of prostate cancer that has progressed after having received other chemotherapy. It works by stopping cell growth and multiplication.

GOMBRICH® cabazitaxel is available as a concentrated solution for infusion in a single presentation consisting of one 60 mg vial and one vial of diluent.

GOMBRICH® cabazitaxel is a taxane that joins the portfolio of products indicated for prostate cancer, together with KESTAVA® abiraterone and DONATAXEL® docetaxel.